Navigation Links
Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Date:4/2/2009

LAVAL, QC, April 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the results of its recently completed North American Phase III clinical trial for its twice-daily formulation of tramadol and acetaminophen (study 06CCL3-001).

Study 06CCL3-001 was a multi-centre, randomized, double-blind, parallel-arm study that compared the efficacy and safety of Labopharm's twice-daily tramadol-acetaminophen formulation to placebo in the treatment of moderate to severe acute low back pain. A total of 277 patients were included in the study. Thirteen percent (13%) of patients in the active treatment group discontinued early (12% due to adverse events) and 5% of patients in the placebo group discontinued early (2% due to adverse events).

Results of the efficacy measures in the study demonstrated a statistically significant difference from placebo in some cases but not in others. An analysis of covariance demonstrated a statistically significant difference from placebo on the Sum of Pain Intensity Differences (SPID) over 50 hours using LOCF (last observation carried-forward) as the imputation method, however, the results were not statistically significant using LOCF/BOCF (baseline observation carried-forward), the primary endpoint. A non-parametric analysis, however, demonstrated statistical significance using both LOCF and LOCF/BOCF as imputation methods. The difference from placebo on the Total Pain Relief (TOTPAR) score was also statistically significant using both LOCF and LOCF/BOCF imputation methods and the patients' global impression of the effectiveness of the study medication was statistically different from placebo. Statistical significance reflects a p-value of less than 0.05 in each of the analyses.

Regulatory authorities throughout the world have different requirements for the analysis and demonstration of efficacy in clinical trials. Labopharm believes that it is likely that the results of this trial are insufficient to support the acceptance of a New Drug Application (NDA) by the Food and Drug Administration (FDA) in the United States. The Company intends to discuss the matter with the FDA's Division of Anesthesia, Analgesia & Rheumatology Products (DAARP) to determine the path forward. The results of this study are however statistically significant under analyses that the Company believes may be accepted for the evaluation of analgesics in Europe, Canada and other jurisdictions. Accordingly, the Company intends to meet with the regulatory authorities for these jurisdictions at the earliest available opportunity in pursuit of regulatory approval. Should the authorities be in agreement, the Company expects that it would submit a regulatory application in those jurisdictions.

The Company will provide additional information following discussions with the various regulatory authorities.

The results of the study have no bearing on the upcoming launch of the Company's once-daily tramadol product in the United States.

About Tramadol-Acetaminophen Combination Products

Tramadol-acetaminophen products leverage the unique but complementary modes of action of each of the active ingredients to provide the analgesic strength of a mild opioid (tramadol) and the rapid pain relief of acetaminophen. Tramadol-acetaminophen combination products were first launched in 2001 in the United States and in 2003 in other major markets and are indicated for the short-term (five days or less) management of acute pain in the U.S. and the symptomatic treatment of moderate to severe pain in the rest of the world.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the price of the Company's shares, the uncertainties related to the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... May kicked off ... people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as ... advice and focus on skin safety and health now and in the future. , ...
(Date:5/4/2016)... ... , ... Recognizing that lifestyle medicine is essential to health and healthcare, ... Katz, MD, MPH, president of the American College of Lifestyle Medicine, as their first ... gratifying,” said Katz. “There is so much opportunity to add years to lives, and ...
(Date:5/4/2016)... ... 2016 , ... Bayco Products has announced the introduction of ... in models NSP-9842XL and NSR-9844XL . , First previewed at SHOT Show ... included CR-123 batteries to produce up to 650 lumens in a variety of ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May 04, 2016 ... products, today revealed the non-toxic benefits of its Tutti Frutti line ... teething pain is just part of the story. These food-grade, silicone ... PVC-, and phthalate-free. , “Many baby toys contain BPA, harmful ...
(Date:5/4/2016)... ... 2016 , ... Fertility Centers of New England announced today the opening of ... Center provides convenient access to care for patients seeking fertility treatment in Maine. “We ... Comprehensive Care in Portland,” said Fertility Centers of New England President and CEO, Joseph ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
Breaking Medicine Technology: